Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Learned treatises and medical textbooks have been an important part of many malpractice cases, on both the plaintiff and defendant sides. But although everyone knows that medical journal articles, textbooks and practice guidelines often offer powerful ammunition for the medical malpractice trial lawyer, the law surrounding the so-called “learned treatise doctrine” remains neither well settled nor universally applied.
What is the history, text, and common interpretation of the learned treatise rule found in the hearsay exceptions to the Federal Rules of Evidence (which many states share)? And how may we address a perplexing question impacting the effective use of a learned treatise ' namely, whether the doctrine permits cross-examination with a learned text absent prior authentication as to that source's reliability?
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.